Our latest hereditary cancer menu enhancements are now available!  

Ambry is dedicated to the search for new, evidence-backed insights that can meaningfully impact patient care. Our latest findings include additional evidence for MLH3, which has resulted in an upgraded gene-disease validity (GDV) for autosomal recessive polyposis and colorectal cancer predisposition. 

This upgraded GDV–along with existing medical management guidelines–is why we’ve enhanced CancerNext^®, CancerNext–Expanded^®, and ColoNext^® to include MLH3 in the base panels.  

Reportable variants for this gene now include “pathogenic,” “likely pathogenic," and “variant of uncertain significance (VUS).” Additionally, if only one pathogenic or likely pathogenic variant is identified, a “carrier” interpretation will be noted due to autosomal recessive inheritance. 

These menu updates are operationalized through Ambry Classifi^®–our proprietary, knowledge-driven engine for turning genetic information into meaningful clinical insights.  

What to know about ordering:  

• Menu enhancements are automatic across digital ordering sources: AmbryPort^®, CARE^®, Progeny^®, and integrated Electronic Health Records (EHRs). 
• If you order CustomNext—Cancer^® and use AmbryPort to place your orders: 
  • For customers with saved panels, click on the “Saved Panels” tab and recreate your favorite panels and add MLH3 if you wish to add it to a saved panel. 

  • For customers who build their panels by indication and gene disease validity, please note that MLH3 has moved from the “Limited GI” grouping to the “GI” grouping (which includes moderate and above GDV). 

• If you use paper Test Requisition Forms (TRFs), please ask your Ambry Account Executive (AE) for updated paper TRFs. Please note: We’re evolving our HCT menu more quickly than ever before! To keep you informed of the latest gene content, we’re making some changes to our paper TRFs to streamline ordering:
  • The updated Cancer (Abbreviated) TRF and the cross-product Comprehensive TRF can be used to order hereditary cancer testing. We now provide a QR code that will point you to AmbryGen.com, to ensure you always have access to the latest gene count and content.
  • We’ve retired the Cancer (Comprehensive) TRF, effective 5/19. 

Key Resources: 

• Want to learn more about our enhanced panels, including gene content, test descriptions, and more? Click on the following: 
  • CancerNext 
  • CancerNext—Expanded 
  • ColoNext 
• Looking for details on MLH3 as it relates to a positive result? Two new resources are available: 
  • MLH3 Positive CMR/UYR (English | Spanish)
  • MLH3 carrier UYR (English | Spanish)
• Need a quick and simple way to update your clinic notes? Click here, select “Gene List,” and then “Copy Gene List” for CancerNext, CancerNext—Expanded, and/or ColoNext. Then, paste the genes into your notes. 
• Looking for the latest TRFs? Click here. 

If you have questions, please contact your Ambry Account Executive. Your local Ambry Genomic Science Liaison (GSL) is available if clinical support would be helpful. You may also contact Client Solutions at (949) 900-5500, info@ambrygen.com, or via our Messages feature within AmbryPort.    
 
Setting the Standard in Genetic Testing 

We invest in the expertise needed for ongoing evaluation of new and existing gene-disease associations to drive improvements in variant classification, smart panel design, and proactive patient care. We’re proud of our uncompromising commitment to setting the standard in genetic testing for over 25 years.